Clinical trial
A Phase I Study of CCI-779, and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme
NCT00316849 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of CCI-779, and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2006
- Completion date
- Not reported
- Enrollment
- 56 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma